The i‑THYMUS project was successfully completed by Genewity between November 2023 and October 2025, with support from the European Union through the European Innovation Council (EIC) Accelerator (Grant Agreement No. 190124491).
The project marked a crucial phase in Genewity’s development and laid the foundation for our transition into a clinical‑stage biotechnology company. The EIC Acceleratorsupport enabled us to strengthen our scientific team and establish essential GMP infrastructure. We are grateful for the trust and support provided by theEuropean Union during this formative period.
About the project
i‑THYMUS focused on developing an innovative therapeutic approach for thymus deficiency, a rare and severe condition in which patients are born without a functional thymus,resulting in severe immune deficiency. The project investigated the use of lentiviral gene therapy to generate thymus organoids derived from a patient’s own cells, with the aim of restoring immune function through a personalized and minimally invasive treatment strategy.
Over the course of the project, Genewity advanced the technology from preclinical development and made large steps to GMP-readiness, including the establishment and validation of a GMP vector manufacturing process. Although the program encountered scientific challenges associated with pioneering innovation, the capabilities, insights, and experience gained through i‑THYMUS continue to shape Genewity’s research strategy and future development programs.
Co‑funded by theEuropean Union
European Innovation Council (EIC) Accelerator
Grant Agreement No. 190124491
Co-funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union. Neither the European Union nor the granting authority can be held responsible for them.
